IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


Catherine Chen

Zhong Lun Law Firm

2025_IFLR1000_Highly_Regarded_Lawyer_1_.png
2025_IFLR1000_Women_Leader_1_.png
Position: Partner
Rating:
  • Highly regarded
  • Women Leaders
Bar Admissions:
China
Practice Areas:
Investment funds
Jurisdictions:
Recent transactional highlights
  • Advised Curon Biopharmaceutical on its US$150 million Series A financing, led by 6 Dimensions, Temasek and Boyu
  • Advised IDG on the formation of semiconductor and AI merger fund (Yiwu Jinhong Fund). This fund has raised RMB10.8 billion and is still in the process of fundraising.
  • Advised client during the whole process of the formation of the Beijing Fund (the “Fund”) jointly established by Tishman Speyer and Shougang Fund. Matter value is about RMB1.8 billion
  • Advised Lilly Asia Ventures on the merger of its portpolios, Hangzhou Just Biotherapeutics and MabSpace Biosciences to create Transcenta Holding Ltd., a world-class biotherapeutics company.
Practice areas
  • Investment funds
  • Private equity
Sector specialisations
  • Financial services
  • Healthcare
  • Investment management
  • Pharma and life sciences
Bar admissions
  • PRC Admitted Lawyer
Association memberships
  • Secretary General, CEIBS Alumni PE Association Shanghai 
  • Member, Shanghai Bar Association Fund Research Committee 
  • Mediator, Shanghai Pudong Professional Mediation Center 
  • Co-chair, Fund Asset Backed Securitization Committee of China Asset Backed Securitization Forum
Academic qualifications
  • LL.M. (East China Univ. of Political Science and Law) 
  • LL.B. (East China Univ. of Political Science and Law)
  • EMBA (China Europe International Business School)
Address:
Shanghai
Tel:+86 21 6061 3599 Email:Contact this practitioner Website:http://www.zhonglun.com/Content/2016/10-14/1643210109.html